TME Pharma targets NOX-A12 licensing deal to fund next-stage GLORIA trial development

• TME Pharma moved into final evaluation of two potential licensing partners for NOX-A12, targeting late-stage development funding and commercialization.
• Partner selection will prioritize the planned next GLORIA study design, regulatory route, commercial timing, cash-flow visibility, and long-term value.
• Strategy for NOX-E36 shifted to pursuing a licensing deal, with talks at an earlier stage than NOX-A12.
• Collaboration on the GRDC project was dropped; the holding company will seek alternative operating businesses to generate cash flow.
• Financial runway extended into Q2 2027 to support deal execution and partner selection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TME Pharma NV published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein.